Scholarlink

Objective <p>To evaluate standardized incidence ratios (SIRs) of cancer in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).</p> Methods <p>A&#xa0;systematic review and meta-analysis of studies from Medline, Embase, and Cochrane databases (inception to May 2025) was performed. Pooled SIRs were analyzed overall and by region, sex, age, AAV subtype, and cancer type.</p> Results <p>Fourteen studies involving 5553 AAV patients and 883 cancers were included. Overall cancer risk was significantly elevated (SIR: 1.767, 95% confidence interval [CI] 1.514–2.063). Regionally, SIRs were increased in Europe (1.717), Asia (2.193), and Oceania (1.740; all <i>p</i> &lt; 0.001). Age-specific analyses showed elevated risks in patients ≤ 60&#xa0;years (SIR: 2.217) and &gt; 60&#xa0;years (SIR: 2.072). Notably increased risks were observed for bladder cancer (SIR: 4.291), leukemia (4.082), kidney cancer (3.202), nonmelanoma skin cancer (3.598), lung cancer (2.082), malignant melanoma (1.701), liver cancer (1.778), oral cavity (1.760), brain (1.912), and colorectal cancer (1.465). No significant increase was found for breast, prostate, stomach cancer, non-Hodgkin lymphoma (NHL), or lymphoma.</p> Conclusion <p>Patients with AAV face a&#xa0;significantly increased risk of cancer, particularly bladder, hematologic, kidney, and skin cancers. These findings support the need for tailored cancer surveillance strategies in AAV management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cancer risk across sex, region, and disease subtype in ANCA-associated vasculitis patients

  • 期刊论文

  • 发表日期：

    2025年9月1日

查看全文
  • Young Ho Lee,
  • Gwan Gyu Song

摘要

Objective

To evaluate standardized incidence ratios (SIRs) of cancer in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Methods

A systematic review and meta-analysis of studies from Medline, Embase, and Cochrane databases (inception to May 2025) was performed. Pooled SIRs were analyzed overall and by region, sex, age, AAV subtype, and cancer type.

Results

Fourteen studies involving 5553 AAV patients and 883 cancers were included. Overall cancer risk was significantly elevated (SIR: 1.767, 95% confidence interval [CI] 1.514–2.063). Regionally, SIRs were increased in Europe (1.717), Asia (2.193), and Oceania (1.740; all p < 0.001). Age-specific analyses showed elevated risks in patients ≤ 60 years (SIR: 2.217) and > 60 years (SIR: 2.072). Notably increased risks were observed for bladder cancer (SIR: 4.291), leukemia (4.082), kidney cancer (3.202), nonmelanoma skin cancer (3.598), lung cancer (2.082), malignant melanoma (1.701), liver cancer (1.778), oral cavity (1.760), brain (1.912), and colorectal cancer (1.465). No significant increase was found for breast, prostate, stomach cancer, non-Hodgkin lymphoma (NHL), or lymphoma.

Conclusion

Patients with AAV face a significantly increased risk of cancer, particularly bladder, hematologic, kidney, and skin cancers. These findings support the need for tailored cancer surveillance strategies in AAV management.